Vaxart Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

false 0000072444 0000072444 2025-01-13 2025-01-13

 

 

 

 

 

 

 

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

 

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company          ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.          ☐

 

 

 

On January 13, 2025, Vaxart, Inc. (the “Company”) issued a press release announcing that an independent Data Safety Monitoring Board recommended that the Company’s Phase 2b clinical trial evaluating its oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator proceed without any modifications.

 

On January 14, 2025, the Company issued a press release, providing business updates on its COVID-19, norovirus, and influenza programs, as well as other matters.

 

Copies of the press releases are attached herewith as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and, other than the quotes by Steven Lo and Dr. James F. Cummings, are incorporated herein by reference.

 

 

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.